News Medicare obesity drug pilot extended after insurer pushback Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.
News Lilly says Foundayo safety confirmed in ACHIEVE-4 trial Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.
News 23andMe study explains variable results with obesity drugs Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
News Generic semaglutide in India, and other weight-loss news Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
News Novo partners with Hims & Hers again, ending GLP-1 spat Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.
News Doctors dismayed by report of NHS AI proposal The British Medical Association has branded a leaked proposal to rein back NHS recruitment and use more AI to compensate a "massive gamble."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
